Evidence map›Paper›PMID 42662613›Full record

ArticleMolecular therapy. Advances2026

Cytokine-independent activation of STAT5 promotes the persistence and function of CD4

Claire E Shudde, Shams Tabrez, Yena Jin, Alejandra Rosario-Crespo, Kora Reid, Atsunori Kaneshige, Longchuan Bai, Yiqing Yang, Shaomeng Wang, Chang H Kim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claire E ShuddeDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
Shams TabrezDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Yena JinDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
Alejandra Rosario-CrespoCancer Biology Training Program, University of Michigan, Ann Arbor, MI, USA.
Kora ReidDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
Atsunori KaneshigeDepartment of Internal Medicine, University of Michigan School of Medicine, Medical School, Ann Arbor, MI, USA.
Longchuan BaiDepartment of Internal Medicine, University of Michigan School of Medicine, Medical School, Ann Arbor, MI, USA.
Yiqing YangDepartment of Internal Medicine, University of Michigan School of Medicine, Medical School, Ann Arbor, MI, USA.
Shaomeng WangDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
Chang H KimDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Adam H CourtneyDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Mechanisms of ligand discrimination by the T cell signaling machineryR35GM146813 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Adam Courtney · 2022 to 2026
$1.9M
Mobilization and trafficking of central ILC progenitorsR01AI173179 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHANG H KIM · 2023 to 2026
$1.7M
NCI NIH HHS P30 CA046592NIAID NIH HHS R01 AI173179NIGMS NIH HHS R35 GM146813
6 · The paper itself

Abstract

Regulatory T cells (Tregs) prevent autoimmunity by suppressing self-reactive immune cells that can damage healthy tissues. Accordingly, therapeutics designed to promote Treg expansion and function, including IL-2 receptor (IL-2R) agonists and adoptive Treg therapies, have been used to treat autoimmune disease. However, the efficacy of these strategies has been hindered by the effects of IL-2 on activated immune cell populations, which can exacerbate inflammation, and by the limited persistence and functionality of Treg therapies. Because Tregs are dependent on IL-2R signaling that is mediated by STAT5, we evaluated a strategy to bypass IL-2R and activate STAT5 in a cytokine-independent manner in CD4

Indexed as

autoimmunitycytokineIL-2JAK-STATLCKSTAT5T cellT cell therapyTreg

Identifiers

PMID42662613
PMCPMC13521244

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.